Please assess the completion status of the following clinical trial:

Trial Title: Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of previously untreated Ph-positive ALL or previously treated in CR after 1-2 courses of therapy or failure after one course of induction chemotherapy without imatinib mesylate.~2. Age \> or = 15 years. Those \< 15 years of age will be treated under compassionate IND.~3. Zubrod performance status \< or = 2 (ECOG Scale, Appendix A).~4. Adequate liver function (bilirubin \< or = to 3.0 mg/dl, unless considered due to tumor), and renal function (creatinine \< or = to 3.0 mg/dl, unless considered due to tumor).~5. Adequate cardiac function as assessed clinically by physical examination.~6. Signed informed consent.~Exclusion Criteria:~1. Active serious infection not controlled by oral or intravenous antibiotics.~2. Treatment with investigational antileukemic agent or chemotherapy agents in the last 7 days before study entry, unless full recovery from side-effects has occurred or patient has rapidly progressive disease judged life-threatening.~3. Active secondary malignancy other than skin cancer (e.g. basal cell carcinoma or squamous cell carcinoma) than in investigator's opinion will shorten survival to less than 1 year.~4. History of Grade III/IV cardiac problems as defined by the New York Heart Association Criteria.~5. Prior history of treatment with imatinib mesylate.~6. Pregnancy or lactating in women of childbearing potential.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyper-CVAD + Imatinib (Type: EXPERIMENTAL): Imatinib 600 mg orally days 1-14, course 1, \& 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m\^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m\^2 IV day 4; Vincristine 2 mg IV days 4 \& 11; \& Dexamethasone 40 mg IV or orally daily days 1-4 \& 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m\^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m\^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).